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IN the course of study on the possibility of autoimmune mechanisms against
tumour, the level of circulating antibodies to the autologous tumour cells was
estimated by cellagglutination titres according to atechniquepreviously developed
in this laboratory (Pikovski, Tal, Schlesinger and Margoliash, 1957). It was
soon found that cross agglutination occurred. It appeared that the sera from
tumour patients contained a factor (AF) which could cause agglutination of, and
be adsorbed by, tumour cells from a variety of sources. This paper represents
an analysis of this phenomenon.
MATERIALS AND METHODS
Cell preparation
Cell suspensions were prepared from some human tumours, several normal
human tissues and some mouse tumours by a previously described technique
(Pikovski, Tal, Schlesinger and Margoliash, 1957). Suspensions of tissue cul-
tures of HeLa cervical carcinoma, KB buccal carcinoma and Chang normal liver
cells were also used. The preparation of the tissue culture suspensions is given
in the following detail using HeLa cultures as the example.
HeLa cultures were grown in Eagle's lact-yeast medium plus 15 per cent of
normal human serum and horse serum, respectively, in milk bottles. After 7-8
days of growth, the medium was pipetted off, and the cell layer washed with 10
ml. of warm (370 C.) phosphate-buffered saline (PBS). The PBS was replaced
by 10 ml. of0-02 per cent Ethylenediamine Tetracetic acid (EDTA) in PBS devoid
of Ca and Mg, and the culture kept at 370 C. for 15-20 minutes. This procedure
loosened the cells from the wall ofthe culture bottle and the EDTA cell suspension
was transferred to a test tube. Clumps of cells were dispersed by repeated
pipetting with a fine Pasteur pipette, taking care to avoid foaming. The suspen-
sion was then centrifuged at 500 r.p.m. for 5 minutes. The supernate was care-
fully removed so as not to disturb the cell pellet. The cells were then resuspended
in 8 ml. of warm RBS and centrifuged as above. The washed cells were counted
and suspended in sufficient normal saline to give a concentration of 4 x 106 cells
per ml.
Agglutination procedure
Sera were diluted fourfold with 0-2 M phosphate buffer (pH 7.0). The pH
ofthe system was critical. 2 x 105 Cells were added to 0 4 ml. ofserum dilutions.C. TAL, T. DISHON AND J. GROSS
The contents were mixed and the tubes incubated for 2 hours at 370 C. They
were then kept at 4° C. for 16 hours and then returned to 370 C. for a further in-
cubation period of 3 hours. The result was considered positive if all the cells of
the tube clumped into a single pellicle which did not break up when shaken
gently. This is shown in Fig. 1. The greatest dilution showing this result was
taken as the titre. In some sera agglutination did not begin to appear till there
was some dilution of the serum. This was analagous to the zone effect for antigen
antibody precipitation where in a zone where the antigen is present in excess the
precipitation is less than maximum. In the mass survey of sera (Table I) the
specimens were coded and then given to the testers, who were therefore unaware
of the origin of the serum.
Adsorption and elution procedure
One ml. of serum was added to 2 ml. of washed packed cells. The tube was
stoppered and mixed. The suspension was incubated at 37° C. for 2 hours and
then left overnight at 4° C. After centrifugation the supernatant was tested for
the presence of the agglutinating factor.
The cells or cell fractions after they had adsorbed the agglutinating factor from
the serum were washed twice with normal saline and then mixed with an appro-
priate volume of 3 per cent sodium chloride. The latter was used as a reagent
to remove the adsorbed protein from the cells or cell fractions. This mixture
was incubated 2 hours at 37° C. and left over night at 40 C. It was then centri-
fuged and the supernate concentrated by dialysis against 25 per cent polyvinyl-
pyrrolidone in normal saline to the desired concentration.
Serumfractionation procedures
Serum pools from normal individuals and those suffering from neoplastic
diseases were separated into 3 fractions, i.e. albumin plus alpha globulin, beta
globulins and gamma globulins by the method of Lever, Gurd, Uroma, Brown,
Barnes, Schmid and Schultz (1951). These were tested for agglutination of
tumour cells. A further fractionation was carried out. Serum pools were treated
with one third their volume of saturated (NH4)2504. The resulting precipitate
was dissolved in distilled water and dialysed against 09 per cent NaCl. The
solution was then treated with an equal volume of 3-6 M (NH4)2SO4 the resultant
precipitate was dissolved in 09 per cent NaCl and dialysed against distilled
EXPLANATION OF PLATE
FIG. 1. This figure illustrates the appearance of the control suspension of tumour cells (left)
and the agglutinating effect (right) of tumour sera on such suspensions. The formation of
such a single pellicle was taken as the criterion for a positive agglutination reaction. The
maximum serum dilution giving such a reaction was taken as the agglutination titre.
FIG. 2.-The figure illustrates the results of immunoelectrophoresis of the beta globulin
fractions from normal and tumour sera when reacted with a rabbit anti-serum against the
fraction from tumour sera. The anode is located to the left and the cathode correspondingly
to the right in these preparations.
The normal serum fraction (A) shows 3 precipitation lines while the tumour serum fraction
(B) shows at least 6 distinct components. The latter was absorbed with placental tissue from
which it was then eluted. The eluate (C) shows the presence of 3 protein components. The
line indicated by the arrow was prominent in all tumour sera tested.
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water (pH7). A precipitate formed which was then dissolved in 0-9 per cent
NaCl or Hank's solution. This solution prepared from tumour sera, contained
the agglutinating factor. It was further analysed by microimmunoelectro-
phoresis (Scheidegger, 1955) using rabbit anti-sera against the fraction and against
whole sera.
Cellfractionation procedures
As a preliminary fractionation, cells were disrupted and separated by centri-
fugation into precipitate and supernatant fractions. The detailed procedure is
as follows-2 ml. of packed tumour cells were suspended in 5 ml. of0-9 per cent
NaCl. The suspension together with 7 g. ofglass powder was shaken in a Nossal
shaker inthe coldfor 30seconds. Afterstanding atroomtemperature for 2 hourto
eliminate the glass, the supernatant was removed and centrifuged at 10,000 r.p.m.
for 8 hour. The precipitate was washed with saline 3 times by centrifugation.
The washings were discarded. The precipitate was tested for its ability to
absorb the agglutinating factor from serum. The supernatant was tested for
possible precipitation activity with normal or tumour sera.
Since the precipitate was found to remove the agglutinating capacity of
positive serum, a further fractionation was carried out (Goebel, Binkley and
Perlman, 1945). Cell suspensions or tissue homogenates were washed with saline
to remove all blood or medium. The material was then treated with about 4
volumes of acetone and this procedure was repeated twice.
The precipitate was then air dried. The dry material was then extracted with
about 4 volumes of ether and air dried. Thirty ml. of undiluted pyridine per
gram of dry residue were added and the mixture homogenized. The pyridine
suspension was then incubated at 370 C. for 1 hour and left at room temperature
overnight. The supernate was removed and the residue again extracted with
15 ml. ofpyridine per gram. The supernatants were pooled and dialysed against
distilled water at roomtemperature untilfreeofpyridine odour. Afineprecipitate
formed, which on the addition of 10 volumes of acetone, sedimented readily by
centrifugation at 3000 r.p.m. for 5 minutes. The precipitate was air dried and
constituted about 3 per cent of the dry weight of the starting material. It was
found to adsorb the agglutinating factor.
RESULTS
Incidence of AF in human sera
A first step in this study, was to determine ifthere was any association between
serum agglutinating capacity and the presence of neoplasia in the serum donor.
HeLa cells were used as the routine test object. Sera were obtained from the
following sources.
(a) 120 patients with histologically proven tumour, attending the tumour
clinic for ambulatory treatment.
(b) 237 typing samples of blood, taken from consecutive blood donors at the
blood bank.
(c) 52 patients consecutively admitted to one of the internal medicine services
at the university hospital. These individuals suffered from a variety of chronic
diseases, about 15 per cent of the cases however were diagnosed as acute myo-
cardial infarction. In none of the patients was there a suspicion of cancer.
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(d) 12 women at delivery and at the same time samples ofcord blood from their
offspring.
The results obtained are given in Table I.
TABLE I.-Mass Survey of Sera
Age of donor Number Number %
Source of serum Mean and range tested positive Positive
Normal individuals
Blood bank . 31 years 237 . 31 13
(18-56)
Term pregnancy . 12 . 12 . 100
Cord blood . 11 . 1 9
Diseased individuals
Non-malignant 47 years 51 8 16
(15-80)
Malignant disease 51 years 120 . 108 90
(17 7-79)
The frequency of agglutination is high in sera from patients with malignant
disease and in sera from pregnant women.
The age distribution in both groups of diseased individuals is similar but the
incidence of AF in the sera of the non-malignant group is significantly lower
(P<0001 by the Chi square test) than in sera of individuals with cancer. Thus
the presence of AF does not appear to be a concomitant of either chronic disease
or of ageing.
An additional difference is seen in the histogram of titres obtained in each of
the test groups (Fig. 3). In cancer sera the modal AF titre is higher than in
either of the two types of controls.
The effect of tumour site on the agglutination reaction is shown in Table II.
The percentage of positives is roughly equivalent for all types. The numbers are
too small to draw any definite conclusions but there is an indication that there
are fewer positive reactions in the sera of patients suffering from tumours of
connective tissue origin.
TABLE II.-Serum HeLa Cell Agglutination Activity According to
Tumour Location
Number Number
Tumour type sera positive 00
Mammary. . 50 . 48 . 96
Female genital . 92 . 18 82
Gastro-intestinal 12 11 92
Respiratory tract 9 8 89
Connective tissue 12 9 . 75
Miscellaneous 15 . 14 94
The nature of the serum agglutinatingfactor (AF)
The separation of serum pools into 3 large fractions was carried out. Only
the beta globulin fraction of the tumour sera contained the agglutinating factor.
The remaining fractions of tumour sera and all fractions of normal sera were
negative for AF.
By further fractionation, using a method designed for the isolation of beta
globulins, a preparation was obtained which was positive for AF. A rabbit
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anti-serum was prepared against the fraction and used for its immunoelectro-
phoretic analysis. The results are shown in Fig. 2. The beta fraction from
normal serum showed about 3 components (Fig. 2A), while the AF-positive beta
fraction usually contains at least 6 antigenically distinct components (Fig. 2B).
This mixture was absorbed with placental preparation and subsequently eluted
with 3 per cent NaCl. The eluted material, causing cell agglutination, showed
the presence of at least 3 protein components (Fig. 20). Fifteen tumour serum
beta fractions and 11 normal serum beta fractions were analysed individually by
immunoelectrophoresis. Twelve of the tumour sera preparations showed more
DISTRIBUTiON OF AGGLUTININ TITRES INTEST
SERA
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FIG. 3.-A comparison ofthe agglutination-titres found in the sera from patients with proven
malignancy and the sera from the two control groups.
lines than the normals and all tumour preparations showed the two prominent
lines to the cathodal side of the well (see arrows Fig. 2B and 2C). The samples
subjected to immunoelectrophoretic analysis were all of the same protein con-
centration, i.e. 15 mg. per ml. Absorption of beta fraction from tumour sera
with an anti-serum against the fraction from normal serum removed all lines.
Cellfactors involved in the agglutination reaction
A number of normal and tumour cell suspensions were tested for agglutin-
ability by tumour sera. Table III shows that, with the exception of KB cells,
all the tumour cells tested, were agglutinated. The normal tissues tested did
not show this reaction. While there seems to be a specificity for the reaction with
tumour cells, it is possible that other types of normal cells might show
agglutination.
A similar pattern was found in relation to the absorption of AF from sera by
various cell types. These results are shown in Table IV, AF was removed from
1 ml. serum by as little as 0-04 ml. of packed cells from various tumour cell pre-
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TABLE III.-The Ayglutinability of Various Cell Types With Tumour Sera
Cell type Agglutinability
Normal tissues-
Human liver cell suspensions . . . 0
Human liver cell in tissue culture (Chang) . .0
Human kidney cell suspension . . 0
Tumour tissues-
Human mammary carcinoma . . . . +
Human colon bladder carcinoma . . . +
Human gall bladder carcinoma . +
Human cervical carcinoma intissue culture (HeLa) +
Human buccal carcinoma in tissue culture . . 0
Mouse mammary carcinoma (RIII) *. . . +
Mouse mammary carcinoma (C3H) . . . +
Mouse ascites tumour (Ehrlich) . . +
parations and human placental homogenate. Normal human liver, kidney or
heart showed no such activity even when as much as 2 ml. of packed tissue was
tested for adsorption from 1 ml. of serum.
TABLE IV.-Specific Absorption of the Agglutinating Factor in the
Serumn of Cancer Patients
Procedure-The active sera were mixed with about 6 x 106 cells or the
equivalent of tissue homogenate, incubated at 370 C. for 2 hours, at 40 C.
for a subsequent 16-18 hours, and then centrifuged. The supernate was
then tested for agglutinating power.
Agglutination titre
Serum Serum Serum Serum Serum Serum
Cell type No. 119 No. 208 No. 71 No. 307 No. 412 PoolNo. 4
Non-absorbed control . . . 1: 64 1:128 1:16 1:128 1: 256 1: 64
RIII mouse mammary carcinoma . 0 0
HeLa human cervical carcinoma . 0
Kidney homogenate human . 1: 64 1:128 1:16 1:128 1: 256 1: 64
Liver ,, ,, . 1: 64 1:128 1:16 1:128 1: 256 1: 64
Heart ,, ,, . 1: 64 1:128 1:16 1:128 1: 256 1: 64
Placenta , . 0
Ehrlich mouse ascites tumour . - 0 --
Human mammary carcinoma . - 0
(-) Not done.
Crude fractionation was carried out of human mammary carcinoma, RIII
mouse mammary carcinoma and Landschutz mouse ascites tumour into a fraction
sedimentable at 10,000 r.p.m. and a supernatant. The washed sediments were
found to absorb AF from tumour sera. The supernates were also tested with
normal and tumour sera for possible immune precipitation reactions-none was
found. This suggested the possibility that the absorbant might be cell wall
material, e.g. lipo-mucopolysaccharide-protein-complex. A procedure used for
extracting such substances from bacteria by means of pyridine (Goebel, Binkley
and Perlman, 1945) was empirically applied to 2 mouse tumour tissues (Land-
schutz mouse ascites, RIII mouse mammary carcinoma), a human mammary
carcinoma and to human placenta. In all cases a water-insoluble precipitate was
obtained which absorbed the agglutinating factor from cancer sera. The ab-
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sorbed material could be eluted by treatment with 3 per cent NaCl solution.
The eluates caused agglutination of HeLa Cells. As to the nature ofthe pyridine-
extractable component, rough analysis ofsuch a preparation from human placenta
shows the presence of a large amount of lipid (66 per cent) some protein (15 per
cent) and the rest carbohydrate.
DISCUSSION
Alterations in the serum of patients with cancer have been extensively in-
vestigated. These have been found primarily in the quantitative and qualitative
composition of the serum proteins (reviewed by Winzler, 1953, and Petermann,
1961). Changes in tumour sera which may cause agglutination of tumour cells
have not previously been reported. However there is a report by Saxen and
Penttinen (1961) that ofall fresh human sera added to tissue cultures ofHeLa cells,
9 per cent cause clumping of the cells and a reduction in their viability. This
effect requires fresh serum and can be removed by absorption with HeLa cells.
Although the effect was observed in 40 per cent ofthe bloods ofpregnant women at
term it occurred in only 26 per cent of the cancer bloods tested (Saxen and
Penttinen, 1962). At the present time it is uncertain whether this clumping
phenomenon is analogous or related to the agglutination effect reported in this
paper.
Some speculation is possible as to the nature ofthe serum agglutinating factor.
Normal human sera have been shown to be cytotoxic to several types of tumour
cells. The toxic factor is absorbed by tumour, placental and lymphatic tissue
(Landy, Michael, Trapani, Achinstein, Woods and Shear, 1960; Ginsburg, Dishon,
Bloch and Gross, 1961). This property is located in a serum protein fraction
which is glycoprotein in nature and consists of a group ofproteins migrating in the
beta 2 region when subjected to immunoelectrophoresis (Dishon and Gross,
unpublished). In fractionating serum from tumour patients, the agglutinating
capacity was found pari passu with the cytotoxic activity described above. All
attempts to separate the agglutinating and cytotoxic activities were so far un-
successful. This localization of the agglutinating factor to the beta globulin is
in accord with the finding of Takada, Saito, Tanino and Ebata (1962) that there
is an additional line demonstrable in the beta 2 region in 81 per cent of all cancer
sera tested, and in 10 per cent of sera from non-cancer patients. However the
serum change reported here differs from the serum factor in pregnancy and malig-
nancy studied by Rottino, Angers and Dool (1962) which has been localized in the
alpha globulin region.
The proteins of normal and tumour sera fractions appear to differ mainly
in their immunoelectrophoretic appearance. Thus the two major immuno-
electrophoretic lines demonstrable in the agglutinating fraction of tumour serum
appear to form longer arcs extending more toward the cathode than the normal.
The beta fraction area from neoplastic or pregnant sera shows an additional
concentric precipitation line which is not visualized in the normal beta serum
fraction. Antigenically, both normal and tumour fractions are the same, since
all the lines of the latter are removed by absorption with anti-serum against the
beta fraction of normal serum. This absorption also removes the agglutinating
and cytotoxic properties. The AF therefore may be due either to the enrichment
of a normal constituent of the beta proteins and/or it may be a metabolic product
of the normally circulating cytotoxic factor. This product could be the result of
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the metabolism of tumour or placental tissues themselves, or the activation of a
normal metabolic mechanism by the presence of these tissues in the body. One
such possibility is a partial proteolytic cleavage of the normal protein. In this
connection it should be noted that Heremans (1960) found that treatment of
beta 2 globulins with papain, in vitro, resulted in an immunoelectrophoretic
pattern consisting of several precipitation lines in addition to the lines given by
the native protein. The possibility that there might be only an enrichment of
the normal beta fraction is unlikely since a fourfold concentration of normal
beta fraction did not cause agglutination.
The possible mechanism of agglutination can now be examined. The serum
protein probably responsible for the agglutination is absorbed onto the HeLa
cells and differs from its counterpart in normal serum by being somewhat more
positively charged. This is indicated by its greater migration toward the cathode
in electrophoresis (see Fig. 2). A second point is the finding that the conditions
for the test require a careful control of pH. Sera from all sources tended to
cause HeLa cell agglutination if the pH of the incubation medium exceeded 7-5
and conversely no agglutination occurred when the environment pH was less
than 6-8. This would suggest that agglutination is a reflection of changes in
surface charge on the HeLa cell caused by the difference in charge ofthe adsorbed
serum protein. Similar mechanisms have been demonstrated to occur in the case
of the agglutination of red blood cells (Sachtleben, Ruhenstroth-Bauer, 1961).
An additional factor involved, may be the level of seromucoid in the serum.
Thus Sato, Amizuka and Sato (1962) have found that the non-specific agglutina-
tion of kieselguhr by human serum is quantitatively inhibited by increasing
additions of human seromucoid. It is established that in cancer there is an
elevation in serum seromucoid (Winzler, 1953). If this component plays a role
in the HeLa cell agglutination system, it is possible that failure to obtain agglutina-
tion in some cancer sera (Table I) may have been due to an excessive elevation of
this serum component.
SUMMARY
It has been found that HeLa cells under appropriate conditions were agglutina-
ted by 90 per cent of 120 sera from patients suffering from proven malignancy.
On the other hand, only 16 per cent of sera from 51 patients suffering from non-
neoplastic chronic disease, and 13 per cent of 237 normal bloods showed such an
effect. Twelve bloods obtained from pregnant women at term all showed
agglutination. A number of tumour cell suspensions were tested for agglutin-
ability, and with the exception of KB (buccal carcinoma cells) all were positive.
Suspensions of normal liver or kidney cells did not agglutinate. The agglutinat-
ing factor was absorbed from serum by cell suspensions from a number of human
and animal tumours and from human placenta. Human kidney, liver or heart
showed no such absorptive capacity. A partial isolation of the tumour cell factor
responsible for the absorption was carried out. The fraction responsible for
agglutination localized to the /6 globulins of the serum protein spectrum. In
tumour sera examined by immunoelectrophoresis, an additional line became
obvious.
The efforts ofthe late Dr. E. Tennenbaum in providing continuous and copious
supplies of HeLa cells were indispensable to this study, for this the authors are
most grateful to her.
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